Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

39.78
+0.13000.33%
Post-market: 39.780.00000.00%19:45 EDT
Volume:2.64M
Turnover:104.39M
Market Cap:7.55B
PE:-11.25
High:39.82
Open:38.96
Low:38.57
Close:39.65
Loading ...

BridgeBio Pharma Director Hannah Valantine Reports Disposal of Common Shares

Reuters
·
12 Jun

BridgeBio Pharma Currently Up Nine Consecutive Days, on Pace for Record Winning Streak -- Data Talk

Dow Jones
·
10 Jun

BUZZ-BridgeBio Pharma gains after H.C. Wainwright raises PT

Reuters
·
10 Jun

BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 Jun

BridgeBio Pharma, Inc. : H.c. Wainwright Raises Target Price to $56 From $53

THOMSON REUTERS
·
09 Jun

BridgeBio Pharma Inc. to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Reuters
·
02 Jun

Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
24 May

BRIEF-Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Reuters
·
20 May

BridgeBio Pharma Inc - Acoramidis Reduces New-Onset Af/Afl Incidence by 17%

THOMSON REUTERS
·
20 May

BridgeBio Pharma Inc - Acoramidis Reduces ACM and Cvh Events by 42% at Month 30

THOMSON REUTERS
·
20 May

BridgeBio Pharma Inc - Acoramidis Reduces Annual Cvh Frequency Due to Af/Afl by 43%

THOMSON REUTERS
·
20 May

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients With Attr-Cm

THOMSON REUTERS
·
20 May

BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis

MT Newswires Live
·
20 May

KKR Genetic Disorder L.P. Reports Disposal of Common Shares of BridgeBio Pharma Inc

Reuters
·
15 May

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
15 May

J.P. Morgan Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
07 May

Director Andrew Lo Reports Disposal of Common Shares of BridgeBio Pharma Inc

Reuters
·
07 May

Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating

MT Newswires Live
·
05 May

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Benzinga
·
03 May

BridgeBio Pharma call volume above normal and directionally bullish

TIPRANKS
·
03 May